AMP-110

Amplimmune is developing AMP-110 for the treatment of autoimmune diseases. AMP-110 targets T-cells and elicits a coinhibitory signal that suppresses T cell responses. In preclinical animal studies, AMP-110 suppresses progression of collagen-induced rheumatoid arthritis (CIA) in DBA/1 mice. Inhibition of RA symptoms is accompanied by decreased proliferation of and cytokine secretion by T cells to collagen as well as reduced recruitment of neutrophils to the lesions. Novel coinhibitory products will be integral in developing a new generation of immunotherapeutics for treating autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, inflammatory bowel disease, autoimmune diabetes, psoriasis, etc.

AMP-224

Many cancers and chronic infectious diseases actively evade and suppress the immune system. On a molecular level, this evasion is due in part to interactions between the proteins PD-1 and B7-H1. Amplimmune is developing AMP-224, a fusion protein that blocks the interaction between PD-1 and B7-H1, for treatment of cancer and chronic infections. AMP-224 works to overcome immune suppression, thereby allowing the immune system to fight successfully against cancer and chronic infections. A mouse version of AMP-224 has shown promising activity in mouse models of cancer and infectious disease. In a mouse model of colon cancer, an optimized treatment regimen with AMP-224 eradicates established tumors of the animals and confers long-term protective anti-cancer immunity.